Bicara's pivotal FORTIFI-HN01 trial reaches key enrollment milestone

 

setting up mid‑2027 interim with added OS analysis

• Interim FORTIFI‑HN01 readout will deliver top‑line efficacy data in mid‑2027, with enrollment now described as substantial.
• Interim OS analysis heightens opportunity and execution bar, with investors focused on design, statistical power, and accelerated versus full approval.
• Management sounded confident, with Q&A centered on HPV‑negative strategy, OS expectations and survival endpoints amid recent competitor data.
• Competitive risk intensifies from petosemtamab and amivantamab, making clearly differentiated overall survival versus earlier EGFR-based entrants in HPV‑negative disease critical.
• Commercial focus on how FICERA can beat first‑mover petosemtamab and amivantamab on pricing, label, chemo‑sparing, while navigating OS approval bar.
• Phase Ib FICERA+pembro in HPV‑negative head and neck shows 54% ORR, 25% CR, ~22‑mo DOR, 9.9‑mo PFS, >21‑mo OS.
• Roughly one‑third of patients in the Phase Ib FICERA study remain alive at three years.
• Core growth driver is FICERA in frontline recurrent/metastatic HPV‑negative head and neck, with breakthrough designation and strong physician interest.
• Head and neck market opportunity is ~50k new HPV‑negative cases annually across US/EU5/Japan, projected to exceed $5B globally by 2030.
• Additional upside from emerging third‑line MSS RAS/BRAF WT colorectal data, including mono and pembro combo, to be presented in January.
• Bicara reported Q3 2026 EPS -$1.04 vs -$0.84 consensus and revenue $0, missing EPS but beating revenue, net loss $71.2M.
• Operating expenses are rising sharply, doubling YoY; R&D was $56.5M vs $33.0M and G&A $19.2M vs $7.7M, reflecting heavy investment.
• Expenses are rising as Bicara scales ficerafusp alfa development/commercial infrastructure pre‑approval, but should stay at Q3 levels through year‑end.
• Company remains a pre‑commercial, development‑stage, loss‑making biotech; revenue, EPS, gross and operating margin metrics and forward guidance were not disclosed.
• Cash and marketable securities of $442.3M provide runway into 1H29, funding FORTIFI‑HN01 through final OS, filing and early launch build.

https://finviz.com/stock?t=BCAX&p=d